Moderna Inc (XTER:0QF)
€ 135.28 -0.14 (-0.1%) Market Cap: 50.44 Bil Enterprise Value: 43.71 Bil PE Ratio: 0 PB Ratio: 4.26 GF Score: 64/100

Moderna, Inc. - Special Call Transcript

Jun 03, 2019 / 12:00PM GMT
Operator

Good morning, and welcome to Moderna's American Society of Clinical Oncology Review Call. (Operator Instructions) Please be advised that the call is being recorded.

At this time, I'd like to turn the call over to Lavina Talukdar, Head, Investor Relations at Moderna. Please proceed.

Lavina Talukdar
Moderna, Inc. - Head of IR

Thank you, operator. Good morning, and welcome to Moderna's ASCO 2019 update call. On today's call, we will review interim data from our Phase I personalized cancer vaccine study that was presented at the American Society of Clinical Oncology meeting over the weekend. You can access the press release issued as well as the studies that we'll be reviewing by going to the investors section of our website at www.modernatx.com.

With me on this call is Stéphane Bancel, Chief Executive Officer; Tal Zaks, Chief Medical Officer; and Lorence Kim, Chief Financial Officer.

Before I begin, I would like to remind everyone that this conference call will include

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot